StemRIM (4599.T) stock price, financials & research

Regular session · JST · Market data may be delayed.

Company profile

StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is currently undergoing Phase II clinical trials for a range of conditions such as epidermolysis bullosa, cerebral infarction, osteoarthritis, chronic liver disease, and cardiomyopathy. Beyond PJ1, StemRIM is also advancing PJ2, another regeneration-inducing medicine utilizing novel peptides A and B; PJ3, a biologic protein designed to promote regeneration; PJ4, a device for collecting a patient's own cells for therapeutic purposes; and PJ5, a stem cell-based gene therapy. Established in 2006, StemRIM is headquartered in Ibaraki, Japan.

Industry: Biotechnology
Sector: Healthcare
Headquarters: JP
CEO: Masatsune Okajima
Listed since: Aug 9, 2019
Employees: 45

Market position

Volume: 219.1K; 1.09× average
Average volume: 200.27K; Average daily volume
Market cap: 22.31B JPY
Beta: 0.95; Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 12.69B JPY
P/E (TTM): -11.88×
P/B (TTM): 3.64×
P/S (TTM): 0×
EV / EBITDA: -6.6×
Earnings yield: -9.80%
Free cash flow yield: -7.40%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: -26.38%
Return on assets: -25.64%
Return on invested capital: -26.51%

Financial health

Debt / equity: 0×
Current ratio: 83.35×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

2.35B JPY+10128.06%

Operating income

−1.97B JPY+5.04%

Net income

−1.93B JPY+4.59%

Metric (JPY)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	—	—	2.35B JPY	22.98M JPY	1.4B JPY
Cost of goods sold	49.5M JPY	44.35M JPY	47.79M JPY	—	—
Gross profit	−49.5M JPY	−44.35M JPY	2.3B JPY	22.98M JPY	1.4B JPY
Research and development	1.37B JPY	1.44B JPY	1.55B JPY	1.4B JPY	1.51B JPY
Selling, general, and administrative	547.85M JPY	594.09M JPY	608.9M JPY	549.24M JPY	436.05M JPY
Operating expenses	1.92B JPY	2.03B JPY	2.16B JPY	1.95B JPY	1.95B JPY
Interest income	22K JPY	—	—	—	8K JPY
Interest expense	—	1K JPY	58K JPY	140K JPY	219K JPY
Depreciation and amortization	49.5M JPY	44.35M JPY	47.79M JPY	49.47M JPY	43.6M JPY
Operating income	−1.97B JPY	−2.08B JPY	142.39M JPY	−1.98B JPY	−593.73M JPY
Net income	−1.93B JPY	−2.02B JPY	168.35M JPY	−1.95B JPY	−582.45M JPY